Evidence map›Paper›PMID 41633991›Full record

ArticleNature communications2026

Single-cell exon deletion profiling reveals splicing events that shape gene expression and cell state dynamics.

Bandana Kumari, Arun Prasath Damodaran, Wilfried M Guiblet, Mei-Sheng Xiao, Amit K Behera, Tyler A On, Carl E McIntosh, Maxwell Teszler, Chelsee Holloway, Sandra Le and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bandana Kumari *RNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Arun Prasath Damodaran *RNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Wilfried M Guiblet *RNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Mei-Sheng XiaoRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Amit K BeheraRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.ORCID http://orcid.org/0000-0002-2087-7016
Tyler A OnMolecular Targets Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Carl E McIntoshRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.ORCID http://orcid.org/0000-0003-3975-1314
Maxwell TeszlerRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Chelsee HollowayMolecular Targets Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Sandra LeRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Nikhil ParabRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA.
Yongmei ZhaoSequencing Facility Bioinformatics Group, Advanced Biomedical and Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-0800-4658
Michael AreggerMolecular Targets Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA. michael.aregger@nih.gov.ORCID http://orcid.org/0000-0001-6443-9870
Thomas Gonatopoulos-PournatzisRNA Biology Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD, USA. thomas.gonatopoulos@nih.gov.ORCID http://orcid.org/0000-0003-2669-2570

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · 2019 to 2025
$3932.6M
Systematic Identification and Functional Characterization of Alternatively Spliced Exons with Phenotypic RelevanceZIABC012033 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONATOPOULOS-POURNATZIS, THOMAS · 2021 to 2025
$3.8M
Establishing Combinatorial Screening Platform Coupled to Single-cell AnalysisZIABC012101 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AREGGER, MICHAEL · 2022 to 2025
$660k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC012033Intramural NIH HHS ZIA BC012101NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001EU.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1ZIABC012033U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1ZIABC012101
6 · The paper itself

Abstract

Alternative splicing is a pervasive gene regulatory mechanism critical for diversifying the human proteome. To systematically investigate its role in cell fate determination, we develop scCHyMErA-Seq, a scalable CRISPR-based exon deletion screening platform integrated with 10x Genomics single-cell transcriptomic readouts. This tool enables efficient exon deletion while simultaneously capturing Cas9/Cas12a guides and polyadenylated transcripts at single-cell resolution. Applying scCHyMErA-Seq to high-throughput profiling of alternative cassette exons, we identify numerous exons with pronounced regulatory effects on gene expression and cell cycle progression. Analysis of the alternative NRF1 exon-7 demonstrates that its inclusion modulates NRF1's regulatory function by influencing its recruitment to the promoters of target genes. Importantly, gene expression profiles generated using scCHyMErA-Seq accurately recapitulate findings from traditional, labor-intensive orthogonal methods, while offering enhanced scalability and efficiency. Overall, scCHyMErA-Seq represents a versatile platform for systematically unraveling the functional impact of alternative splicing by directly linking specific splicing variants to transcriptional phenotypes.

Indexed as

Alternative SplicingExonsSequence DeletionSingle-Cell AnalysisCRISPR-Cas SystemsGene Expression ProfilingHumansSingle-Cell Gene Expression Analysis

Identifiers

PMID41633991
PMCPMC12868714

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.